Juan A. Arnaiz — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Juan A. Arnaiz appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13

Recruiting shown0

Roles1

SourceClinicalTrials.gov

Clinical trials

13 shown

Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.NCT04353193 · lead sponsor · 2020-06-01

UNKNOWN

Safety & Efficacy of Dual Therapy With Raltegravir/LamivudineNCT02284035 · lead sponsor · 2015-09-27

COMPLETED

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveNCT02470650 · lead sponsor · 2015-06-01

WITHDRAWN

Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted DarunavirNCT02337322 · lead sponsor · 2015-03-31

UNKNOWN

Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol LevelsNCT01935674 · lead sponsor · 2013-09-01

COMPLETED

Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral SuppressionNCT01471821 · lead sponsor · 2011-10-01

COMPLETED

Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal BleedingNCT01095185 · lead sponsor · 2010-11-01

COMPLETED

Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected PatientsNCT00978237 · lead sponsor · 2009-10-01

COMPLETED

Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid MetabolismNCT00759070 · lead sponsor · 2008-09-01

UNKNOWN

A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV InfectionNCT00679497 · lead sponsor · 2008-06-01

COMPLETED

Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/MclNCT00532168 · lead sponsor · 2007-09-01

COMPLETED

Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).NCT00979706 · lead sponsor · 2005-03-01

COMPLETED

Intermittent ART in Primary HIV InfectionNCT02300623 · lead sponsor · 2000-03-01

COMPLETED

Drugs studied in this sponsor's trials

10 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Juan A. Arnaiz as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

abacavir / lamivudine1

darunavir1

dolutegravir1

lamivudine1

octreotide1

placebo1

rilpivirine1

ritonavir1

Sponsor roles

lead sponsor13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.